Proactiveinvestors United Kingdom TyraTech, Inc. https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom TyraTech, Inc. RSS feed en Sun, 26 May 2019 16:33:25 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - TyraTech moving to phase II of its development pipeline ]]> https://www.proactiveinvestors.co.uk/companies/news/203701/tyratech-moving-to-phase-ii-of-its-development-pipeline-203701.html TyraTech PLC (LON:TYR) is proving there is life after Vamousse – the hair lice treatment it sold last year.

Alliance Pharma agreed to pay US$17.5mln for the worldwide rights to Vamousse - with US$13mln coming upfront, followed by US$4.5mln of contingent payments tied to sales milestones.

The deal leaves TyraTech free to focus on developing technology for the control of insects and parasites, where it sees a possible US$6bn market.

Animals have pests too

Fantastic though the Vamousse product was, the potential in the animal health market dwarfs that of the human head lice treatment market.

The world's population is expanding at a rapid rate, and with it, the need for protein, and the world simply cannot afford the loss of animal production caused by parasites.

Treatments do exist, of course, to combat parasites but again we are talking old-school solutions that come with concomitant dangers to the environment and the food chain.

No one wants to see a return to the days of mass use of DDT, for instance.

Like all of TyraTech's technology, though, its PureScience products are environmentally friendly, plus, of course, they work.

As chief executive officer Bruno Jactel has previously observed, not all insecticides are so beneficial to the food chain.

“We also note with great interest the recent issues regarding the use of unauthorized insecticides to control red mites in poultry facilities in Europe and the resulting effects on egg production. We believe that our pesticide-free products deliver competitive efficacy against the red mite, which is a major problem in Europe. We have already initiated field studies in France and plan to progress this opportunity as quickly as resources and the regulatory situation permit," Jactel said.

Meanwhile, the PureScience range of animal health products targeting poultry production operations has also made good progress from a small base with limited marketing support.

The latter – limited marketing support – was always a problem for the company in terms of realising the product potential of Vamousse, and it is to be hoped that the proceeds from the sale of the head lice product will give the company the wherewithal to develop its animal health technology.

Looking to jump-start the development pipeline

In 2018, the operational goals are to expand the market penetration of the products already launched and to jump-start its development pipeline, focusing on products targeting the biggest markets – namely, the control of internal parasites in production animals.

In May 2018, the company reported on progress made on several fronts.

PureScience Poultry Mite unit sales were up 250% year-on-year, albeit from a modest base, with the company having achieved nationwide distribution in the USA with MWI Animal Health, which is the biggest distributor of animal health products in the US.

The company is in the process of expanding the usage of Poultry Mite Dust to Europe where the market is larger, estimated at US$40 million a year.

Sales of its Outsmart equine repellent to its partner, SmartPak, were up sharply on the same period of 2017, and SmartPak intends to release a new formulation of the product this year for use on sensitive parts of a horse, such as around the eyes.

“We are first focusing our development pipeline on the control of coccidiosis, a protozoan parasite of poultry,” the company told shareholders in May.

Coccidiosis, a parasite of the guts in poultry, is very common. Worldwide, the annual cost inflicted by coccidiosis to commercial poultry has been estimated at US$2 billion. The worldwide market for products to control coccidiosis is estimated at US$1 billion annually and current chemical or biological solutions are not satisfactory, TyraTech said.

“We could anticipate a streamlined launch for this future product because it would benefit from the commercial operations already established by our Poultry Mite Dust in the poultry sector,” the company said.

The worms have turned​

The company also plans to direct its development effort on controlling intestinal and stomach worms in ruminants, a worldwide market valued at US$3 billion.

Ruminants are frequently infested by intestinal and stomach worms and the annoying parasites have developed resistance to the pharmaceutical products currently used.

Multiple test-tube studies have demonstrated that TyraTech's specifically designed formulations control several species of intestinal worms, while a pivotal study has been conducted on live pigs, independently managed by the University of Georgia (USA), which showed that TyraTech’s product significantly reduced the load of worms in the pigs by 70%.

More studies will need to be designed to optimise the formulations and demonstrate that they are also effective in ruminants but TyraTech regards the studies completed so far as significant milestones.

“After numerous positive lab studies, we are now moving to the Phase II of our development pipeline to test our products against internal parasites directly on animals. Initial probe studies are encouraging and show that we are moving in the right direction,” Jactel claimed.

Having sold off its money-spinner, Vamousse, the company made a loss from continuing operations in 2017 of US$4.4mln, which was a slight improvement on the year before. 

]]>
Fri, 24 Aug 2018 12:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203701/tyratech-moving-to-phase-ii-of-its-development-pipeline-203701.html
<![CDATA[News - TyraTech making significant progress in developing new products ]]> https://www.proactiveinvestors.co.uk/companies/news/197521/tyratech-making-significant-progress-in-developing-new-products-197521.html TyraTech Inc (LON:TYR) has seen strong growth in sales of its poultry mite dust and its equine fly repellent.

The life sciences company is now focused purely on nature-derived insect and parasite control products following the sale of its Vamousse head lice shampoo, and it has been encouraged by the recent progress made in the development of innovative solutions to producers of animal proteins.

READ Tyratech focused on animal health

Starting from a modest base, unit sales of PureScience, its product to control mites on chickens, have more than doubled versus last year on a moving annual total basis and are still growing steadily, TyraTech said.

The company is in the process of expanding the usage of its PureScience poultry mite dust to Europe, where the market is larger.

Sales of its equine fly repellent product, OutSmart, to its partner SmartPak, are up sharply year-on-year in the first part of 2018.

Despite a good start to the year, TyraTech is not expecting a strong fly season due to the sustained cold weather.

The group ended the year with around US$14.4mln in cash and cash equivalents, of which around US$8.4mln was distributed to shareholders in January 2018 by way of a tender offer.

Overall, total revenue for 2017 was US$1.2mln versus US$658,000 in 2016. Of this, product revenue was US$872,000 compared to US$325,000 in 2016, an increase of 169%. This increase in product revenue is primarily a result of the full launch of OutSmart equine fly repellent and the expansion of distribution of its PureScience product to control mites.

The loss from continuing operations for 2017 was US$4.4mln versus US$4.5mln the year before. The loss before tax from continuing operations narrowed to US$3.9mln from US$4.5mln in 2016.

"We are pleased to show that, in a short period of time, we are making significant progress in developing new products and solutions for some of the largest animal health market segments and to answer some of the biggest unmet needs,” said Bruno Jactel, the chief executive officer of TyraTech.

“Now that we have set-up our new strategic focus, all our efforts will be concentrated on rolling-out the commercialisation of existing products in the US and in other countries, and developing new products for some of the biggest animal health market segments. Our clear short-term objective is generating sales of existing products and reaching the most significant product development milestones," he added.

Shares in TyraTech were down 0.15p at 2.25p in early deals.

Photograph of the TyraTech team preparing for field trials in France against the poultry red mite, the most significant laying hen pest in Europe. Most countries have an infestation level above 90%. Annual cost to European poultry production is estimated at ~€240M.#TYRU #TYR pic.twitter.com/moSQkun3uI

— TyraTech, Inc. (@TyraTechNews) March 12, 2018 ]]>
Wed, 23 May 2018 08:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197521/tyratech-making-significant-progress-in-developing-new-products-197521.html
<![CDATA[Media files - TyraTech 'making significant progress' across its animal health products and solutions ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9264/tyratech-making-significant-progress-across-its-animal-health-products-and-solutions-9264.html Thu, 10 May 2018 15:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9264/tyratech-making-significant-progress-across-its-animal-health-products-and-solutions-9264.html <![CDATA[News - Tyratech focused on animal health ]]> https://www.proactiveinvestors.co.uk/companies/news/193258/tyratech-focused-on-animal-health-193258.html TyraTech PLC (LON:TYR) intends to focus on opportunities in the animal health sector after the sale of its Vamousse-branded hair lice treatment.

In December 2017, it was agreed that Alliance Pharma would pay up to US$17.5mln for the worldwide rights to Vamousse - with US$13mln coming upfront, followed by US$4.5mln of contingent payments tied to sales milestones.

WATCH: Fresh start for Tyratech with new strategic focus on animal health

The deal puts Vamousse in the hands of a company that is better placed to put the marketing support needed to get the product better known in the marketplace and leaves TyraTech free to focus on developing technology for the control of insects and parasites, where it sees a possible US$6bn market.

Losses were sharply reduced in the first half of 2017

The company, still in the growth stage of its development, slashed losses from operations in the first half of 2017 to US$711,000 from US$1.52mln in the same period of the previous year.

Loss before tax narrowed dramatically to £254,000 from a loss the year before of £1.52mln, helped by a £456,000 gain on the sale of intellectual property to Envance Technologies.

The sale to Envance also provided the company with an upfront payment of US$500,000, received subsequent to the half year-end. TyraTech ended the reporting period with cash and cash equivalents of US$1.3mln, down from US$1.8mln at the end of 2016.

TyraTech may have sold off some of the family silver, but the cash will undoubtedly come in useful – the company will also receive a small share of any profits from Envance’s sales of the products - and it now has a major global consumer company in its corner.

Chief executive officer Bruno Jactel believes the deal is an excellent endorsement of TyraTech’s technology by one of the largest consumer products companies in the world.

“Although the agreement is not expected to be transformational in terms of profitability, it provides us with further confidence in the significant value of our IP [intellectual property] and know-how and the potential and value of our Animal Health and Personal Care portfolios," Jactel said.

Animals have pests too

Fantastic though the Vamousse product was, the potential in the animal health market dwarfs that of the human head lice treatment market.

The world's population is expanding at a rapid rate, and with it, the need for protein, and the world simply cannot afford the loss of animal production caused by parasites.

Treatments do exist, of course, to combat parasites but again we are talking old-school solutions that come with concomitant dangers to the environment and the food chain.

No one wants to see a return to the days of mass use of DDT, for instance.

Like all of TyraTech's technology, though, its PureScience products are environmentally friendly, plus, of course, they work.

As Jactel pointed out in the company’s interim results, not all insecticides are so beneficial to the food chain.

“We also note with great interest the recent issues regarding the use of unauthorized insecticides to control red mites in poultry facilities in Europe and the resulting effects on egg production. We believe that our pesticide-free products deliver competitive efficacy against the red mite, which is a major problem in Europe. We have already initiated field studies in France and plan to progress this opportunity as quickly as resources and the regulatory situation permit," Jactel said.

“The re-formulated Outsmart equine fly repellent has been well received by customers and is on course to exceed our partner, SmartPak's, expectations for the year,” Jactel noted.

Meanwhile, the PureScience range of animal health products targeting poultry production operations also made good progress from a small base with limited marketing support.

The latter – limited marketing support – was always a problem for the company in terms of realising the product potential of Vamousse, and it is to be hoped that the proceeds from the sale of the head lice product will give the company the wherewithal to develop its animal health technology.

]]>
Thu, 15 Mar 2018 15:22:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/193258/tyratech-focused-on-animal-health-193258.html
<![CDATA[News - TyraTech confirms it is proceeding with Vamousse sale to Alliance Pharma ]]> https://www.proactiveinvestors.co.uk/companies/news/189309/tyratech-confirms-it-is-proceeding-with-vamousse-sale-to-alliance-pharma-189309.html TyraTech Inc (LON:TYR) has confirmed that its deal with Alliance Pharma plc (LON:APH) for the sale of the Vamousse branded hair lice treatment will now proceed with immediate effect.

The natural health product company confirmed in a stock market statement that the proposed transaction was approved by shareholders at an AGM yesterday.

Earlier this month, it was agreed that Alliance Pharma would pay up to US$17.5mln for the worldwide rights to Vamousse - with US$13mln coming upfront, followed by US$4.5mln of contingent payments tied to sales milestones.

Tyratech shares were up around 10% on Thursday while Alliance also edged into positive territory.

Alliance chief executive John Dawson said: "The completion of this acquisition provides Alliance a third International star brand with best in class technology.

“There is also real potential for further growth through our substantial global network of distributors."

Following the sale, Tyratech intends to focus on opportunities in the animal health, for control of insects and parasites, where it sees a possible US$6bn market.

]]>
Thu, 28 Dec 2017 08:53:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/189309/tyratech-confirms-it-is-proceeding-with-vamousse-sale-to-alliance-pharma-189309.html
<![CDATA[Media files - Fresh start for Tyratech with new strategic focus on animal health ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/8510/fresh-start-for-tyratech-with-new-strategic-focus-on-animal-health-8510.html Fri, 08 Dec 2017 13:05:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/8510/fresh-start-for-tyratech-with-new-strategic-focus-on-animal-health-8510.html <![CDATA[News - TyraTech's hard choices paying off ]]> https://www.proactiveinvestors.co.uk/companies/news/183826/tyratech-s-hard-choices-paying-off-183826.html Pest control technology firm TyraTech PLC (LON:TYR) has had to make some hard choices this year but the reasoning behind them seems sound.

After carrying out a strategic review, Bruno Jactel, chief executive, said the company concluded that it did not have sufficient resources from operating cash flow alone to fund the next phase of its growth and unlock the full value of its assets.

Its response was to restructure into two divisions, one focused on animal health and the other on human health, to help it capitalise on the potential in both businesses. Initially, both entities will remain 100% owned by TyraTech.

The company is best known for its Vamousse head lice treatment, which in terms of effectiveness knocks old-school treatments into a cocked hat, but for as long as Proactive Investors has been following the TyraTech story, it has been known that the company's technology has other potential applications, particularly the massive agricultural livestock market.

WATCH TyraTech 'looking to unlock potential' in animal health

It also took a long hard look at where its marketing dollars could best be used and opted to focus, for now, on the US, where its Vamousse head lice treatment has been outperforming the market in terms of sales growth.

The product has been well received in other geographies too, but as a consumer good it needs heavyweight promotion to improve its chances of making its way into shoppers’ baskets, and the company has opted to concentrate on its biggest market.

The move seems to be paying off, judging by its interim results, released in September.

TyraTech said like-for-like sales of Vamousse product are outstripping the market in the US, contributing to a handy increase in first half revenues to US$4.3mln from US$4.1mln in the first half of last year.

The company, still in the growth stage of its development, slashed losses from operation to US$711,000 from US$1.52mln the previous year.

Loss before tax narrowed dramatically to £254,000 from a loss the year before of £1.52mln, helped by a £456,000 gain on the sale of intellectual property to Envance Technologies.

The sale to Envance has also provided the company with an upfront payment of US$500,000, received subsequent to the half year-end. TyraTech ended the reporting period with cash and cash equivalents of US$1.3mln, down from US$1.8mln at the end of 2016.

TyraTech may have sold off some of the family silver, but the cash will undoubtedly come in useful – the company will also receive a small share of any profits from Envance’s sales of the products - and it now has a major global consumer company in its corner.

READ TyraTech gets major boost as global group licenses pest control tech

Jactel believes the deal is an excellent endorsement of TyraTech’s technology by one of the largest consumer products companies in the world.

“Although the agreement is not expected to be transformational in terms of profitability, it provides us with further confidence in the significant value of our IP [intellectual property] and know-how and the potential and value of our Animal Health and Personal Care portfolios," Jactel said.

Va-va-Vamousse

The company's revolutionary head lice treatment, Vamousse, is now stocked on both sides of the Atlantic by several well-known retailers, such as Walmart, Walgreen, Sainsbury's, Boots and Superdrug, and though it has yet to knock the market leaders off their perches – backed as they are by big companies with heavy marketing budgets – it has clearly established itself as “the best of the rest”.

Not bad for a company valued at around £5mln.

“Head lice protection is an emergency purchase so you have to be able to find it in the store next door, so achieving good distribution was a key milestone,” TyraTech's chief executive officer, Bruno Jactel, told Proactive Investors.

Having established Vamousse as what Jactel called “the first of the outsiders”, the challenge is to start taking market share from the two market leaders, both of which are old school lice treatments of the type that are gradually losing their effectiveness, as successive generations of lice build up resistance.

Some of these products require that the treatment remains on the hair for several hours in order to work; Vamousse's technology is different in that it effectively kills the lice and their eggs by dehydration within 15 minutes of being applied.

The formulation is pesticide free and the fashion conscious will be pleased to learn that it is fine to apply a conditioner after using Vamousse.

Animals have pests too

The potential in the animal health market dwarfs that of the human head lice treatment market.

The world's population is expanding at a rapid rate, and with it the need for protein, and the world simply cannot afford the loss of animal production caused by parasites.

Treatments do exist, of course, to combat parasites but again we are talking old-school solutions that come with concomitant dangers to the environment and the food chain.

No one wants to see a return to the days of mass use of DDT, for instance.

Like all of TyraTech's technology, though, its PureScience products are environmentally friendly, plus, of course, they work.

The only problem for the AIM minnow is that developing the animal health technology will require a (cow) shed-load of money, hence the decision to set-up the business as a discrete unit, which should make it easier for potential partner companies to share the development load.

The stark realisation that TyraTech is a David competing on a battleground populated by Goliaths has seen TyraTech’s share price halve in the last year but management’s response seems to have been the right one, judging by the sharply reduced losses at the half-year stage.

The market may also be coming round to that point of view, given the shares rose 20% on the release of the results.

]]>
Tue, 12 Sep 2017 12:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/183826/tyratech-s-hard-choices-paying-off-183826.html
<![CDATA[Media files - Tyratech boss focused on unlocking full value of the business ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/8068/tyratech-boss-focused-on-unlocking-full-value-of-the-business-8068.html Tue, 12 Sep 2017 11:04:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/8068/tyratech-boss-focused-on-unlocking-full-value-of-the-business-8068.html <![CDATA[News - Tyratech soars as it slashes losses ]]> https://www.proactiveinvestors.co.uk/companies/news/183799/tyratech-soars-as-it-slashes-losses-183799.html Tyratech, Inc. (LON:TYR LON:TYRU) saw its shares gain today after the pest control technology firm said its products outperformed a recovering US head lice market in the first half of 2017.

In late morning trading, Tyratech shares were almost 4.9%, or 0.05p higher at 1.08p.

In a statement, the AIM-listed company said like-for-like sales of its Vamousse head lice product are outstripping the market in the US, contributing to a handy increase in first half revenues to US$4.3mln from US$4.1mln in the first half of last year.

WATCH: Tyratech boss focused on unlocking full value of the business

Management took the decision to focus is marketing and commercial resources supporting Vamousse on the US market, and reduce its commitment to other markets – most notably the UK, where a slow-down in Vamousse sales has been seen as a consequence.

READ: Tyratech gets major boost as global group licenses pest control tech

The company, still in the growth stage of its development, slashed losses from operation to US$711,000 from US$1.52mln the previous year.

Loss before tax narrowed dramatically to £254,000 from a loss the year before of £1.52mln, helped by a £456,000 gain on the sale of intellectual property to Envance Technologies.

The sale to Envance has also provided the company with an upfront payment of $500,000, received subsequent to the half year-end. Tyratech ended the reporting period with cash and cash equivalents of US$1.3mln, down from US$1.8mln at the end of 2016.

Losses to narrow

Chief executive Bruno Jactel said the company should show a significant reduction of its net losses over the full year when compared with 2016.

“This will be achieved through a combination of sales growth and tight control of operational expenses, together with the sale of IP to Envance,” Jactel said.

“Looking to 2018, we have hopes of further increasing the distribution for our Vamousse range of products in the US. We also note with great interest the recent issues regarding the use of unauthorized insecticides to control red mites in poultry facilities in Europe and the resulting effects on egg production. We believe that our pesticide-free products deliver competitive efficacy against the red mite, which is a major problem in Europe. We have already initiated field studies in France and plan to progress this opportunity as quickly as resources and the regulatory situation permit,” he added.

Non-executive chairman José Barella said the company’s previously announced strategic review is still in progress.

“Our focus remains to unlock the full value of the business for shareholders. The process is progressing well and we intend to provide a full update to the market once we have reached concrete conclusions as to the best outcome for all our shareholders," Bartella said.

 -- Adds share price, video link --

]]>
Tue, 12 Sep 2017 07:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/183799/tyratech-soars-as-it-slashes-losses-183799.html
<![CDATA[News - Tyratech gets major boost as global group licenses pest control tech ]]> https://www.proactiveinvestors.co.uk/companies/news/180319/tyratech-gets-major-boost-as-global-group-licenses-pest-control-tech-180319.html TyraTech Inc (LON:TYR LON:TYRU) has received a big endorsement of its household pest control technology through a licensing deal with a major global consumer company.

The company's intellectual property and household pest knowledge is currently licensed to its US joint venture Envance, but this will now be sub-licensed to the global group.

Tyratech’s range of personal care products, including its Vamousse head lice treatments and Guardian range of insect repellents are not included, nor is its range of animal health products.

Bruno Jactel, chief executive, said it was an excellent endorsement of TyraTech’s technology by one of the largest consumer products companies in the world. 

“Although the agreement is not expected to be transformational in terms of profitability, it provides us with further confidence in the significant value of our IP and knowhow and the potential and value of our Animal Health and Personal Care portfolios."

Jactel added it will be a benefit in three ways: First, through the sharing of technology, joint ownership and access to any new intellectual property developed; secondly through a small share of the profit Envance makes and an additional upfront cash fee of US$500,000.

Finally, TyraTech will receive a fee for research and development services in line with the terms of its existing agreement with Envance, a joint venture between American Vanguard Corporation (NYSE:AVD 86.67%) and TyraTech 13.33%.  AMVAC is also a 15.15% shareholder in TyraTech.

]]>
Tue, 04 Jul 2017 15:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/180319/tyratech-gets-major-boost-as-global-group-licenses-pest-control-tech-180319.html
<![CDATA[Media files - Tyratech 'looking to unlock potential' in animal health ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/7418/tyratech-looking-to-unlock-potential-in-animal-health-7418.html Tue, 09 May 2017 09:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/7418/tyratech-looking-to-unlock-potential-in-animal-health-7418.html <![CDATA[News - Tyratech to restructure to unlock potential in animal health arm ]]> https://www.proactiveinvestors.co.uk/companies/news/177494/tyratech-to-restructure-to-unlock-potential-in-animal-health-arm-177494.html Tyratech PLC (LON:TYR) is to restructure into two divisions focused on animal and human health respectively to help it capitalise on the potential in both businesses.

After carrying out a strategic review, Bruno Jactel, chief executive, said the company concluded that it did not have sufficient resources from operating cash flow alone to fund the next phase of its growth and unlock the full value of its assets.

That was despite a good year for Vamousse, its flagship anti-lice treatment, which saw sales rise 10% to US$5.9mln in the US and by 27% to £1.3mln in the UK.

WATCH: Tyratech 'looking to unlock potential' in animal health

Group net sales overall rose by 7% to US$7.2mln while loses for the year were slightly reduced to US$2.31mln.

Jactel said Vamousse had largely driven the improvement.

“The brand made substantial progress in 2016, increasing its market share and retail distribution in the UK and in the US.

“We added a major distributor, Rite Aid, in the US and placed new products in CVS and gained commitment to expand the offering at Walgreens in 2017.”

In animal health, Tyratech launched products in the equine and poultry segments with major distributors and the biggest producers of poultry and eggs in the US.

Jactel also believes the animal health business ultimately has larger growth opportunities, but further investment to support R&D will require either a partner and/or additional investment.

Consultants have been appointed with the aim of completing the reorganisation by the end of the financial year.

Vamousse is in the final stages of an external validation while an external validation of the value of the animal health business has just got underway.

In the short-term, Jactel said the focus will be growing Vamousse in the US and in the UK without major expansion in existing and new geographies and to roll-out the existing animal health products in the US.

]]>
Tue, 09 May 2017 08:03:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/177494/tyratech-to-restructure-to-unlock-potential-in-animal-health-arm-177494.html
<![CDATA[Media files - Tyratech boss 'happy to be able to grow the brand' amid challenging market conditions ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/6914/tyratech-boss-happy-to-be-able-to-grow-the-brand-amid-challenging-market-conditions-6914.html Tue, 14 Feb 2017 10:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/6914/tyratech-boss-happy-to-be-able-to-grow-the-brand-amid-challenging-market-conditions-6914.html <![CDATA[News - Double digit growth for TyraTech’s head lice products in 2016 ]]> https://www.proactiveinvestors.co.uk/companies/news/172938/double-digit-growth-for-tyratechs-head-lice-products-in-2016-172938.html A market recovery in the US at the end of 2016 helped TyraTech, Inc.’s (LON:TYR; LON:TYRU) head lice brand, Vamousse, to post double-digit year-on-year growth in 2016.

The Vamousse brand – which is stocked by the likes of Walmart, CVS and Walgreens in the US and by Tesco, Boots and Sainsbury’s in the UK – also gained market share against its major competitors in both territories.

The growth comes against a difficult backdrop for the market as a whole in the US. Back in September, TyraTech said it expected Vamousse’s growth to slow in the second half due to a wider “deceleration” in the head lice treatment market in the US.

However, the market picked up again at the end of the year to finish almost flat in the US for 2016.

Despite the recovery, TyraTech kept a cautious eye on its costs just in case.

The North Carolina-based group said it still expects results to be in line with market expectations and its cash position to be in excess of US$1.7mln.

Aside from Vamousse, the company’s Guardian non-toxic mosquito and tick repellent is set for a trial run in Kroger stores – the largest grocery chain in the US – for the 2017 season.

TyraTech has also finalised the development of its OutSmart non-toxic insect repellent for horses, with an additional patent filing being made for the new formulation.

OutSmart was pre-launched by TyraTech’s partner SmartPak at the end of 2016 and the full launch is expected in the second quarter of this year.

The outlook for 2017 is positive as well. Even being “cautious” with its expectations, the firm is still confident that it can post double digit revenue growth in the coming 12 months as well.

Final results for the year ended 31 December 2016 will be announced before the end of April.

]]>
Thu, 09 Feb 2017 15:05:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/172938/double-digit-growth-for-tyratechs-head-lice-products-in-2016-172938.html
<![CDATA[Media files - Tyratech, Inc's Bruno Jactel discusses Vamousse and the group’s very good first half ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/6006/tyratech-inc-s-bruno-jactel-discusses-vamousse-and-the-groups-very-good-first-half-6006.html Mon, 19 Sep 2016 10:46:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/6006/tyratech-inc-s-bruno-jactel-discusses-vamousse-and-the-groups-very-good-first-half-6006.html <![CDATA[News - Tyratech seeing continued growth of Vamousse ]]> https://www.proactiveinvestors.co.uk/companies/news/165759/tyratech-seeing-continued-growth-of-vamousse-165759.html Continued traction of its head lice shampoo Vamousse saw TyraTech Inc (LON:TYR, LON:TYRU) post a 31% increase in sales in the first half to the end of June against the same period last year.

Gross product sales increased 21% to US$4mln against US$3.3mln in the same time in 2015, the life sciences group said.

Despite strong competition, it gained market shares in both the UK and the USA, where the product is now found in Walgreens, CVS and Rite Aid.

The firm also reported its first sales in France, while Vamousse was included in the NHS Minor Ailments Scheme in the UK.

The period also saw the group enter the animal health market which, it says, represents a large and growing opportunity and the group made first sales of its animal health products, with the first three now being actively promoted.

Looking ahead, chief executive Bruno Jactel said the firm expected the second half to be stronger than the first as we enter the "back to school" period for Vamousse sales and it "actively promotes" its animal health portfolio.

But he added the rate of growth will be lower than previously anticipated and revenue and net loss for the full year will be below market expectations - mainly due to recent data showing a slowdown for head lice products in the US compared with strong growth in previous years.

For the six months to 30 June, operating expenses were steady at US$3.8 million (2015: US$3.7 million), while the net loss was around the same as last year at US$1.5mln.

Cash and equivalents were US$2.1 million, compared to US$4mln as at the end of 2015.

]]>
Tue, 13 Sep 2016 07:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/165759/tyratech-seeing-continued-growth-of-vamousse-165759.html
<![CDATA[Media files - Strong business growth heads off competitors, says TyraTech, Inc. chief ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/5345/strong-business-growth-heads-off-competitors-says-tyratech-inc-chief-5345.html Mon, 01 Aug 2016 15:04:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/5345/strong-business-growth-heads-off-competitors-says-tyratech-inc-chief-5345.html <![CDATA[News - TyraTech sees continued traction with head lice shampoo ]]> https://www.proactiveinvestors.co.uk/companies/news/128722/tyratech-sees-continued-traction-with-head-lice-shampoo-128722.html Life sciences tech group TyraTech Inc (LON:TYR, LON:TYRU) said its head lice shampoo product Vamousse is continuing to gain market share and sales were as expected in the first half.

In a pre-close update ahead of results for the six months to end June, the firm said trading continued the 'upward trend'  seen in prior periods, with unit sales of the Vamousse head lice product line continuing to progress, and operating expense efficiencies now being realised.  

"These trends are anticipated to continue throughout the second half. The board expects the net loss over the year to remain in line with current market expectations," it told investors.

Revenues from Vamousse sales have been modestly affected by currency translation effects on UK sales and by factors, such as the sale or return policy associated with one new US customer. These impacts are expected to continue through the rest of the year, it added.

Meanwhile, on its PureScience insect and parasite control range for animals, the roll-out in the first half was slower than expected mainly due to the time of completing the field trials, which are making good progress, and it is now expected that revenues will be in the second half of the year.

Three products were launched for poultry and swine production at the end of the half, it noted.

In April, the group, which focuses on developing natural insecticides, said gross profit rose 31.4% to $4.6mln on a 154% increase in gross product revenue to $7.1mln in the year to the end of December.

Gross revenue lifted 51% to $7.4mln while the group’s net losses fell to $2.3mln from $5.1mln a year ago.

]]>
Thu, 28 Jul 2016 07:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/128722/tyratech-sees-continued-traction-with-head-lice-shampoo-128722.html
<![CDATA[Media files - Tyratech chief focused on “the pathway to profitability” ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/4882/tyratech-chief-focused-on-the-pathway-to-profitability-4882.html Tue, 12 Apr 2016 11:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/4882/tyratech-chief-focused-on-the-pathway-to-profitability-4882.html <![CDATA[News - TyraTech plans expansion as revenue rises ]]> https://www.proactiveinvestors.co.uk/companies/news/124677/tyratech-plans-expansion-as-revenue-rises-124677.html Life sciences technology group TyraTech Inc (LON:TYR) posted higher annual gross profits and revenue and said it was targeting expansion into new markets.

TyraTech, which focuses on nature-derived insect and parasite control products, said gross profit rose 31.4% to $4.6mln on a 154% increase in gross product revenue to $7.1mln in the year to the end of December.

Gross revenue lifted 51% to $7.4mln while the group’s net losses fell to $2.3mln from $5.1mln a year ago.

The company significantly expanded the number of stores stocking its flagship Vamousse head lice treatment and shampoo.

More than 24,000 shops in the US, including Walmart (NYSE:WAL), Walgreens, CVS and Rite Aid, and over 7,800 in the UK, including Superdrug, Boots, Sainsbury’s (LON:SBRY) and Tesco (LON:TSCO), now stock Vamousse.

TyraTech undertook its first major expansion into continental Europe with the launch of the full Vamousse range and Guardian personal mosquito and tick repellent in France.

Morrisons (LON:MRW) has also begun selling Vamousse in the UK.

The group also plans to launch its PureScience insect and parasite control range of products for animals.

PureScience, which will be initially targeted at the poultry market, uses plant-derived active ingredients with powerful natural insecticidal properties.

TyraTech is launching the product at a time when existing synthetic-based insecticides face increasing levels of resistance and regulatory pressure.

Chief executive Bruno Jactel said the company plans to launch its products in other mainland European countries.

“We made good progress in 2015 and the board of directors is confident we will continue to grow sales of our existing products as well as deliver innovative new products,” he said.

Shares in TyraTech rose 0.12p, or 4%, to 3.25p in early London trading.

House broker Whitman Howard, which has a 'buy' recommendation on the stock, expects the company to break even at a pre-tax earnings before interest level in 2017.

"Tyratech’s outlook statement appears positive," the broker said in a note.

"It refers to a combination of expansion across both lines of consumer health (Vamousse and Guardian) and a major step-up in animal health which clearly benefits from sizable addressable markets."

]]>
Tue, 12 Apr 2016 09:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/124677/tyratech-plans-expansion-as-revenue-rises-124677.html
<![CDATA[News - TyraTech welcomes industry veteran as new chairman ]]> https://www.proactiveinvestors.co.uk/companies/news/124611/tyratech-welcomes-industry-veteran-as-new-chairman-124611.html Natural pesticides group TyraTech Inc (LON:TYR, LON:TYRU) has named 60-year-old industry veteran José Geraldo Ramalho Barella as its new chairman with immediate effect.

Currently in the role, Alan Reade will step down but remain on the board as a director, the group said.

Beginning his career in 1982 in the chemical industry, first at steel maker Cosipa and later with Alcoa, Barella has along list of appointments on his CV, including Rhodia Pharma and Rhone Poulenc Agro.

In 2001, he joined Merial, the animal health joint venture of Merck and Aventis, based in the USA to lead the companion animals division. In 2007 he was appointed CEO of Merial and when in 2011 Merial became the Animal Health Division of Sanofi, he was appointed Senior VP Animal Health and CEO of Merial.

During 12 years there, Merial grew sales from US$1.5 billion to US$2.8 billion, while earnings before interest and tax increased from US$200 million to US$870 million with Frontline one of the most successful products in the history of Animal Health.

From April 2013 to December 2015 he joined the advisory board of biotech mABxience with a focus in the development, manufacturing and commercialisation of biosimilars for human health.

And last year he was hired as chairman of Tel-Aviv based Netafim - a world leader in irrigation with a global footprint and sales in excess of US$750 million.

Reade said today: "I have known and worked with José for many years and his industry knowledge, experience and contacts will be invaluable as TyraTech continues to commercialise its technology and ramps-up over the coming years.  My intention is to remain with the Company for a couple of months to help smooth the transition at a very important stage in our development."

Barella said he was excited about the role. "I have been aware of TyraTech for some time.  They have developed world class technology with multiple market commercial applications."

]]>
Mon, 11 Apr 2016 07:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/124611/tyratech-welcomes-industry-veteran-as-new-chairman-124611.html
<![CDATA[News - TyraTech Inc has sizeable opportunity in animal health market, says Whitman ]]> https://www.proactiveinvestors.co.uk/companies/news/123744/tyratech-inc-has-sizeable-opportunity-in-animal-health-market-says-whitman-123744.html TyraTech Inc (LON:TYR, LON:TYRU) is undervalued and has a sizeable opportunity in the animal health market, says house broker Whitman Howard, which rates shares a 'buy'.

The firm has developed nature-derived insect and parasite control products and its flagship offering currently is the Vamousse headlice treatment, which has gained significant traction.

The anti-lice remedy and preventative shampoo has found its way into mainstream US retailers - notably Wal-Mart -  and is making progress within the drug stores and in the UK market, said analyst Chris Wickham.

But earlier this year, TyraTech unveiled the launch a new line of animal health biocide products branded 'PureScience', which will initially be aimed at poultry producers and be distributed in the USA.

The range currently includes three formulations to control adult flies, immature flies and mites in industrial poultry production though Tyratech eventually expects to expand the range to cattle and pigs.

"TyraTech’s animal health opportunity is sizeable and probably not appreciated fully by the market," said the analyst, adding that animal health and agribusiness was a preferred growth “hot spot” within the broker's overall coverage of fast moving consumer goods (FMCG) stocks.

"There is a clear case for sustained growth in both the companion and production animal markets.

"The latter should be driven by higher consumer protein consumption. Avoidance of parasites infestation is important as, in our view, TyraTech’s products should succeed in aiding farms’ output and profitability."

The broker also applauds the group's business model, which outsources manufacturing and sales, so is structured to maximise flexibility and ensures scalability when launching new products and entering new geographies.

From 2016, the company will be able to finance expansion internally with sales and, ultimately, profit growth benefits accruing directly to shareholders, it also notes.

"TyraTech operates in the highly prized area of consumer health, in addition to having a substantial opportunity with animals."

Wickham argues this 'elegant combination' is not borne out in the group's current valuation and bases its potentially conservative 11p price target (current price: 3p) on 4.5 times' the average of 2016 and 2017 net sales.

]]>
Wed, 16 Mar 2016 10:50:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/123744/tyratech-inc-has-sizeable-opportunity-in-animal-health-market-says-whitman-123744.html
<![CDATA[News - TyraTech strikes deal with large US retailer Rite Aid ]]> https://www.proactiveinvestors.co.uk/companies/news/122853/tyratech-strikes-deal-with-large-us-retailer-rite-aid-122853.html Life sciences group TyraTech (LON:TYR, LON:TYRU) announced today that its head lice treatment Vamousse is set to be found in major US retailer Rite Aid Corporation after striking a new distribution agreement.

With the addition of this Fortune 500 firm, Vamousse is now available in all of the top four retail pharmacy chains in the US and nationwide can be found in more than 24,000 individual stores, including Walmart, Walgreens, and CVS Health.

Chief executive Bruno Jactel said: "We recognize that the purchase of head lice treatment is for almost all parents and caregivers is an emergency buy.

"When a child is identified with a lice infestation, you want to find a resolution immediately.  For this reason, achieving strong and comprehensive distribution in our major target markets is paramount. 

“Our strategy has been to make sure that the consumer can find our product in whatever store is closest to home and then to drive brand awareness through our marketing programs.  Broad distribution helps us achieve the best return on investment for our marketing spend.”

TyraTech has also made progress in increasing Vamousse’s UK presence having increased its store presence in Tesco and Sainsbury’s to achieve coverage of more than 7,800 retail stores.

"We continue to build on the success of establishing the Vamousse head lice franchise and monetizing our technology.  These additional distribution agreements across major retailers in both the US and UK are strong validation for the value and efficacy of our products for consumers and retailers alike," said Jactel.

Vamousse is now widely on sale throughout the UK and US - and is the fastest growing national brand head lice product in the US..  ]]>
Tue, 23 Feb 2016 10:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/122853/tyratech-strikes-deal-with-large-us-retailer-rite-aid-122853.html
<![CDATA[Media files - TyraTech boss says animal health is natural next step to grow ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/4627/tyratech-boss-says-animal-health-is-natural-next-step-to-grow-4627.html Mon, 08 Feb 2016 11:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/4627/tyratech-boss-says-animal-health-is-natural-next-step-to-grow-4627.html <![CDATA[News - TyraTech happy with step-change year ]]> https://www.proactiveinvestors.co.uk/companies/news/121983/tyratech-happy-with-step-change-year-121983.html TyraTech (LON:TYR) said 2015 was a step change year for the business despite a previously flagged distribution issue affecting revenues.

The natural insecticide group saw sales increase year-on-year and healthy gross margins as the roll-out of its Vamousse head lice treatment gathered momentum.

Vamousse is now widely on sale throughout the UK and US and is the fastest growing national brand head lice product in the States. 

Launches in other European markets are scheduled for the next couple of years.

Tyratech also recently launched its PureScience animal health range of products in the US, which will be distributed  by MWI Animal Health (NASDAQ:ABC), the leading animal health distribution company in the US.

Total revenues will be marginally lower than expected while the net loss will be in line with market forecasts, Tyratech said.

]]>
Mon, 01 Feb 2016 09:22:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/121983/tyratech-happy-with-step-change-year-121983.html
<![CDATA[News - Tyratech fills finance post with tech specialist ]]> https://www.proactiveinvestors.co.uk/companies/news/121530/tyratech-fills-finance-post-with-tech-specialist-121530.html Natural insecticides group TyraTech (LON:TYR)  has appointed Erica Boisvert as its new chief financial officer. 

Most recently in a similar position at clean tech group Southern Energy Management, Boisvert will have overall responsibility for the company's investor relations as well as its financial operations.  

In a twenty year career, Boisvert also spent eight years at SlickEdit Inc, a software company where she eventually became president.  

Bruno Jactel, chief executive, said: "TyraTech is at a pivotal stage of its development as a global company. 

“It is important that we invest in our senior management infrastructure and strengthen our operational capability. 

"Erica has extensive senior management experience within businesses that successfully monetised their technology and attracting someone of her calibre is great news."

]]>
Wed, 20 Jan 2016 09:18:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/121530/tyratech-fills-finance-post-with-tech-specialist-121530.html
<![CDATA[Media files - Tyratech chief “very excited” by new product launch ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/4550/tyratech-chief-very-excited-by-new-product-launch-4550.html Thu, 14 Jan 2016 16:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/4550/tyratech-chief-very-excited-by-new-product-launch-4550.html <![CDATA[News - Tyratech launches new range of animal insecticides ]]> https://www.proactiveinvestors.co.uk/companies/news/121262/tyratech-launches-new-range-of-animal-insecticides-121262.html TyraTech (LON:TYR) is to launch a new line of non-toxic animal health biocide products this year.

The PureScience-branded products will initially be aimed at poultry producers and be distributed in the US by MWI Animal Health (NASDAQ:ABC).

The range currently includes three formulations to control adult flies, immature flies and mites in industrial poultry production though Tyratech eventually expects to expand the range to cattle and pigs. 

Bruno Jactel, Tyratech’s chief executive, said: "PureScience represents a significant first step into the animal health market and the partnership with MWI will allow us to expand further in the coming years.

"Flies, roaches, mites and other insects spread disease and pose a significant health risk to livestock and farm animals."

Purescience represented a new and important animal health franchise to complement its Vamousse head lice range, he said, adding the products differed from traditional synthetic insecticides as they utilised plant-derived active ingredients that had powerful natural insecticidal properties.

“They will be launched at a time when existing synthetic-based insecticides are suffering from increasing levels of resistance and regulatory pressure," he said.

Robert Rowland, an entomologist at MWI added: "I have used TyraTech's products in the field and seen the excellent results for example on poultry mites.”

]]>
Wed, 13 Jan 2016 08:04:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/121262/tyratech-launches-new-range-of-animal-insecticides-121262.html
<![CDATA[Media files - New funds key to Vamousse growth, says TyraTech chief exec ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/4335/new-funds-key-to-vamousse-growth-says-tyratech-chief-exec-4335.html Thu, 05 Nov 2015 08:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/4335/new-funds-key-to-vamousse-growth-says-tyratech-chief-exec-4335.html <![CDATA[News - TyraTech raises funds for Vamousse marketing drive ]]> https://www.proactiveinvestors.co.uk/companies/news/117048/tyratech-raises-funds-for-vamousse-marketing-drive-117048.html Natural insecticide group TyraTech (LON:TYR) will use the proceeds of a £3.2mln funding to grow head lice treatment Vamousse and kick-start a new animal-focused product.

Shares will be placed at 3p per share with £1.2mln of the money earmarked for Vamousse for marketing support in the US and UK and geographic expansion in Germany and Australasia.

A further £1mln will be spent on the  PureScience range, which is aimed at animal production facilities, with poultry producers the initial target. The remainder will be used across the business generally.

Bruno Jactel, chief executive, said Vamousse is now available in over 20,000 stores in the US and approximately 7,000 in the UK. In the four weeks ending 6 September 2015 Vamousse was ranked the number three over-the-counter brand in the US, he said.

He said Tyratech is now ready to expand distribution of Vamousse both in existing markets and elsewhere and the money raised will enable it to boost its market share more rapidly. 

]]>
Wed, 04 Nov 2015 08:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117048/tyratech-raises-funds-for-vamousse-marketing-drive-117048.html
<![CDATA[News - TyraTech may miss second half targets but voices confidence about 2016 ]]> https://www.proactiveinvestors.co.uk/companies/news/111081/tyratech-may-miss-second-half-targets-but-voices-confidence-about-2016-111081.html --- Updates with comment from chief executive, share price ---

Life sciences group TyraTech (LON:TYR) blamed distribution issues for lower-than-expected second-half trading, but said it was confident about 2016.

After a strong first half in which sales rose 267%, they continued to rise since June 30, but had been behind the firm's forecast expectations.

The group, which develops natural insect and parasite control products, said second-half results would be lower than expected if the trend continued - but materially better than the first half.

TyraTech said its Vamousse lice treatment & protective shampoo, which drove the increase, was the fastest-growing branded head lice product in the US and was extremely well positioned.

It now has new products in more than 8,000 stores in chains such as Wal-Mart and CVS in the US.

But it said it continued to be in uncharted territory from a forecasting perspective, not having experienced, as yet, a full year with current distribution arrangements in place.

Chief executive Bruno Jactel said it had taken a while to get the products "on the shelf".

"We suffered from that at the beginning of the year and lost a few months of sales, but we're well prepared for next year," Jactel told Proactive Investors in an interview.

"I think we're very well positioned to have fast growth in the year coming up."

Shares in Tyratech fell 0.62p to 4.88p in afternoon trading in London.

TyraTech said it was poised to develop and launch alternatives to pesticides in a number of other target markets.

Since the end of the first half, TyraTech has launched Vamousse Treatment and Shampoo in Ireland, introduced Vamousse shampoo in Boots and secured a distribution deal with Well pharmacies, previously known as the Co-op. It also wants to expand in other European markets.

It added: "There is good evidence the market for head lice products is growing year-on-year and we believe we're well positioned with our product range and the quality of our customer base to benefit from this growth.

"In addition, we believe there will be additional contributions next year from the animal health and equine products."

Gross profit increased by about 150% to $2mln from the effect of new product commercialisation.

Loss from operations reduced to $1.7mln for the first half of 2015 from $2.6mln a year ago, resulting primarily from increased product sales.

The net loss before and after taxes decreased to $1.5mln from $3.1mln last time.

]]>
Thu, 24 Sep 2015 15:55:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/111081/tyratech-may-miss-second-half-targets-but-voices-confidence-about-2016-111081.html
<![CDATA[Media files - TyraTech’s shampoo to keep flying off shelves, says CEO ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/4176/tyratechs-shampoo-to-keep-flying-off-shelves-says-ceo-4176.html Thu, 24 Sep 2015 11:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/4176/tyratechs-shampoo-to-keep-flying-off-shelves-says-ceo-4176.html <![CDATA[News - UPDATE - TyraTech enjoys sharp up-tick in revenue ]]> https://www.proactiveinvestors.co.uk/companies/news/108231/update-tyratech-enjoys-sharp-up-tick-in-revenue-108231.html ---ADDS BROKER COMMENT AND SHARE PRICE---

The top line of parasite control specialist TyraTech (LON:TYR) headed sharply north last year, as the company secured distribution deals for its head lice products.

In the US, the company secured nationwide distribution for its Vamousse lice treatment with the world's largest retailer, Walmart, and is also got stocked by online giant Amazon.

In the UK, 2014 saw the lice treatment picked up by Boots, Tesco, Superdrug and Sainsbury's, with the product launch supported by a memorable TV advertising campaign.

Overall gross revenue for 2014 was up 250% year-on-year to US$4.9mln from US$1.4mln in 2013, with the increase largely due to US$2.8mln of sales of products, which supplemented the collaborative revenues the company has traditionally received.

Gross profit shot up to US$3.5mln from US$0.6mln in 2013, lifting the gross margin to 74.9% from 46.3%. Of course, product launches cost money, and business development costs and expenses rose US$3.0mln from the year before, despite which the loss before tax only broadened by US$0.7mln to US$5.1mln.

At the end of the year the company has cash plus cash equivalents of US$2.2mln, up from US$0.9mln at the end of 2013.

Trading in the new financial year has been in line with expectations, but the company reminded investors that the head lice treatment market is a seasonal one, with the big selling period being when kids go back to school after the summer holidays.

While Vamousse is garnering most of the attention, the company's Guardian personal mosquito and tick repellent and its OutSmart equine fly repellent are both now available, and building up reputations in the marketplace.

“We have demonstrated the strength of our technology in different market segments, the breadth of our product portfolio, and the agility of our business model,” said Bruno Jactel, chief executive officer of TyraTech.

“We believe that the medium term outlook for the company is strong as our technology continues to be commercialised into new products and geographies," he added.

House broker Allenby said TyraTech's revenue and profits were in line with its forecasts, and although cash burn was US$400,000 higher than it had anticipated, the company is still in position to self-finance its progression to cash break-even and profitability.

The 2014 sales figure included an eight-month contribution from Vamousse, but Allenby cautioned against extrapolation the numbers over a 12-month period as sales of head lice treatments are highly seasonal.

“In the short term to medium term we expect TyraTech to increase the distribution base for Vamousse treatment in both the USA and the UK and to increase the availability of its protective shampoo,” Allenby's Ian Jermin said.

“Expansion of the technology into new market segments (insect repellent with the Guardian brand and animal health products) will continue but given the need to conserve cash full commercialisation of these products will probably remain secondary to the Vamousse product range,” Jermin speculated.

The broker is leaving its forecasts unchanged for now.

It expects the company to end 2015 with cash of around US$1.5mln, with the cash pile rising to US$2mln by the end of 2016, but much depends on the rate of production expansion and trading conditions.

Nevertheless, Jermin remains hopeful that the company can achieve cash break-even and positive earnings before interest, tax, depreciation and amortisation (EBITDA) without having to raise any more cash.

Shares in TyraTech were off 0.25p at 4.5p in late afternoon trading, but are up 12.2% year-to-date.

]]>
Mon, 22 Jun 2015 15:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/108231/update-tyratech-enjoys-sharp-up-tick-in-revenue-108231.html
<![CDATA[News - TyraTech secures US distribution deal for insect repellant ]]> https://www.proactiveinvestors.co.uk/companies/news/107338/tyratech-secures-us-distribution-deal-for-insect-repellant-107338.html Parasite control specialist TyraTech (LON:TYR) has signed an exclusive distribution agreement with SmartPak Equine to launch an insect repellent called Outsmart Fly Spray.

The product will be distributed by SmartPak, which is the largest retailer of equestrian products in the United States; SmartPak will commercialise and distribute OutSmart Fly Spray throughout the USA. 

It is the first TyraTech product to be used directly on animals, thus opening up a whole new sector of the animal health market to TyraTech.

The insect repellent is powered by TyraTech’s Nature Technology, which is the core technology behind the company’s Guardian range of insect repellent products.

Outsmart Fly Spray is designed to be effective against house flies, stable flies, mosquitoes and ticks. The formula is non-toxic and is free of permethrin, pyrethroids, pyrethrins, and DEET, making it safe and effective for both horses and riders. 

“Our distribution arrangement, in which SmartPak is responsible for the promotion and distribution of OutSmart, provides us with a rapid, efficient and economical route to market,” said Bruno Jactel, chief executive officer of TyraTech.

“We have always promoted the breadth of the potential uses and applications of our core technology, and whilst our main focus remains strongly on our lead Vamousse brand, broadening our portfolio and application base in partnership with a major company like SmartPak is very much adding further strength to our business," he added.

Donnie Steele, chief marketing officer at SmartPak, said there is a definite market need for an effective and safe fly repellent for horses and riders.

“We look forward to strengthening our relationship with TyraTech and extending our product offering using TyraTech's innovation platform,” Steele said.

Shares in TyraTech rose 1.1% to 4.80p in the first hour of trading.

]]>
Tue, 26 May 2015 09:06:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/107338/tyratech-secures-us-distribution-deal-for-insect-repellant-107338.html
<![CDATA[News - TyraTech raises cash by reducing stake in Envance JV ]]> https://www.proactiveinvestors.co.uk/companies/news/68168/tyratech-raises-cash-by-reducing-stake-in-envance-jv-79427.html Life sciences firm TyraTech (LON:TYR) is to receive around US$500,000 in cash after rejigging its Envance agricultural products joint venture arrangements.

With the strong demand for TyraTech's Vamousse head lice treatments, the company has opted to focus more on its core markets of personal care, where Vamousse is it flagship range, and animal health, where it has a range of anti-parasitic products.

Envance Technologies was formed in partnership with American Vanguard (NYSE:AVD) subsidiary AMVAC, to develop and commercialise a range of innovative pest control solutions for global consumer, commercial, and agriculture pest control markets.

Under the new joint venture (JV) terms, TyraTech will receive cash in repayment of loans and the transfer of some equity in Envance, which it will re-invest into working capital and geographical expansion of its Vamousse branded products.

Under the new arrangements, AMVAC's share of the JV has grown to 86.77% from 60% and, conversely, TyraTech's share has fallen to 13.33% from 40%.

"Over the past twelve months, having validated our entry into the personal care market with the successful launch of our Vamousse branded products in both the USA and the UK, our investment and growth pathway will be through geographic expansion of our current products, commercialisation of products in development, and continued development of our pipeline across both the personal care and animal health markets," said Bruno Jactel, chief executive officer of TyraTech.

"With our sharpened strategic focus in these two markets, I am very pleased that together with TyraTech's strategic investor, AMVAC, we were able to achieve our goal of strengthening Envance as the organisation best suited to develop and commercialise TyraTech's technology for the agriculture, household, and lawn and garden markets," he added.

]]>
Mon, 20 Apr 2015 07:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/68168/tyratech-raises-cash-by-reducing-stake-in-envance-jv-79427.html
<![CDATA[Media files - Head lice proving to be big business for TyraTech in US ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/3204/head-lice-proving-to-be-big-business-for-tyratech-in-us-3204.html Thu, 09 Apr 2015 16:03:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/3204/head-lice-proving-to-be-big-business-for-tyratech-in-us-3204.html <![CDATA[News - TyraTech adds Walgreens to impressive US client list ]]> https://www.proactiveinvestors.co.uk/companies/news/67838/tyratech-adds-walgreens-to-impressive-us-client-list-79066.html TyraTech’s (LON:TYR) Vamousse head lice treatment is to be stocked by Walgreens, the largest pharmacy chain in the USA.

The Walgreens listing follows the recent announcement of the Vamousse listing with CVS, the second largest pharmacy chain in the USA, while the product is also in the catalogues of the top three pharmaceutical distributors in the USA.

It is expected that the Vamousse treatment product will be available in the majority of Walgreens stores nationwide in the USA from May 2015.

“The Walgreens listing, following the recent CVS listing and the listing with Walmart last year will put our Vamousse head lice treatment in three of the top four pharmacy retailers in the USA,” said Bruno Jactel, chief executive officer of TyraTech.

“This is a significant step in the implementation of our strategy of making our products widely available to customers and building a national brand in the US,” he added.

TyraTech’s joint-broker, Allenby Capital, saluted the deal.

“Through Walmart, CVS and Walgreens the product is now listed in 20,000 major stores in the USA and via the pharmacy distributors is available in numerous smaller independent, local and regional pharmacies across the country.

“Clearly, this is exceptionally good news and as well as providing an endorsement of the product from the USA’s largest pharmacy chain, the listing provides near comprehensive coverage of the head lice Treatment in the USA with the listing of Vamousse Protective Shampoo to follow in due course,” the broker said.

Allenby said the deal “reinforces the distribution assumptions” supporting its 2015 forecasts, which were based on a full 12 months of sales of Vamousse Treatment in Walmart stores and the listing of the product in other major chains in the USA for the majority of 2015.

Shares in TyraTech climbed 5.7% to 5.02p on the news.

]]>
Wed, 08 Apr 2015 08:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/67838/tyratech-adds-walgreens-to-impressive-us-client-list-79066.html
<![CDATA[News - TyraTech says second biggest pharmacy chain in the US to stock Vamousse ]]> https://www.proactiveinvestors.co.uk/companies/news/67433/tyratech-says-second-biggest-pharmacy-chain-in-the-us-to-stock-vamousse-78633.html ---ADDS BROKER COMMENT AND SHARE PRICE---

TyraTech's (LON:TYR) Vamousse head lice treatment continues to be adopted by US pharmacy chains, with CVS the latest chain to stock it.

CVS Pharmacy is the second largest pharmacy chain in the USA, with more than 7,600 stores, and it serves some 100 million American customers each year.

It is expected that the Vamousse treatment product will be available in the majority of CVS stores nationwide in the USA from the end of April 2015.

TyraTech already has deals with the top three pharmaceutical distributors in the USA, but chief executive officer Bruno Jactel said the CVS listing is probably the company's most important milestone this year "as it firmly establishes our product in the pharmacy segment in the USA and significantly enhances the profile of our brand."

In the UK, Tesco has decided to take the Vamousse treatment product out from behind its in-store chemist counter and place it on general display, which will significantly increase product visibility.

Tesco has also confirmed that it will almost double the number of stores stocking TyraTech's Vamousse Treatment product.

Tyratech's broker, Allenby Capital, said: "These announcements, together with the news earlier this month of a listing of the Vamousse products by the top three US pharmaceutical distributors, represent further important milestones in the Vamousse roll-out and all form part of the assumptions underpinning our earnings forecasts.

"We believe that an improving results profile and positive news flow, such as today's announcement, will provide the necessary traction to reverse the recent downtrend in the shares implying that the current share price offers a very attractive buying opportunity for investors," it added.

The DI shares of TyraTech (LON:TYRU) were up 5.8% at 6.35p in lunchtime trading.

]]>
Wed, 25 Mar 2015 13:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/67433/tyratech-says-second-biggest-pharmacy-chain-in-the-us-to-stock-vamousse-78633.html
<![CDATA[News - UPDATE - TyraTech head lice product gaining traction with further US distribution listing ]]> https://www.proactiveinvestors.co.uk/companies/news/66715/update-tyratech-head-lice-product-gaining-traction-with-further-us-distribution-listing-77846.html ---ADDS BROKER COMMENT AND SHARE PRICE---

TyraTech’s (LON:TYR) Vamousse head lice product is gaining significant traction in the US where it is already stocked by the world’s largest retailer.

This morning it said the only natural remedy in this category is now listed with AmerisourceBergen.

Amerisource is the second-biggest distributor of pharmaceutical products in the States, so the deal paves the way for distribution to the large network of independent pharmacies there.

Vamousse is already listed with McKesson and Cardinal Health – respectively number one and number three in this sector.

TyraTech revealed last week the Day Lewis independent pharmacy group would become a UK stockist, joining the Lloyds chain.

It already has deals with Boots, Superdrug, Sainsbury and Tesco on this side of the Atlantic. In the US, the giant Walmart is also sells the breakthrough foam.

It said the new listings with US distributors represented an important milestone for TyraTech, “providing the essential first step in accessing the approximate 20,000 independent pharmacies in the USA”.

Chief executive Bruno Jactel added: "The team is very excited by the growth opportunities presented by the continually expanding distribution network for Vamousse products."

The shares, up almost 40% in the last three months, marked time in early afternoon trade, changing hands for 5.54p each, which values the firm at £17mln.

Allenby Capital, broker to TyraTech, said the company remains on course to “profitably commercialise” its portfolio of nature derived insect and parasite control products.

“This latest addition to the Vamousse distribution network supports our proposition that the group remains well placed to deliver maiden profits and (depending on the pace of expansion plans) positive cash flow in 2016,” it told clients.

]]>
Tue, 03 Mar 2015 12:23:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/66715/update-tyratech-head-lice-product-gaining-traction-with-further-us-distribution-listing-77846.html
<![CDATA[News - UPDATE - TyraTech says two more UK pharmacy chains to stock Vamousse ]]> https://www.proactiveinvestors.co.uk/companies/news/66524/update-tyratech-says-two-more-uk-pharmacy-chains-to-stock-vamousse-77632.html ---ADDS BROKER COMMENT AND SHARE PRICE---

TyraTech's (LON:TYR) revolutionary Vamousse head lice treatments will be available in more than 1,300 new distribution outlets from March.

The company announced two new distribution deals with big names in the UK pharmacy sector.

Day Lewis, the largest independent pharmacy chain in the UK with more than 200 outlets, is already stocking Vamousse and has been since January 2015.

Lloyds Pharmacy, which has a distribution network of more than 1,600 outlets in the UK, is expected to commence stocking Vamousse products from March 2015.

TyraTech said the Vamousse range is already stocked in Britain by Boots, Superdrug, Sainsbury's, Tesco and Rowlands.

"Increasing the physical distribution points is particularly important for head lice products that tend to be emergency purchases. Customers need to be able to find the products close to home in order to solve their head lice problems as fast as possible," the company said.

Put another way, customers should not be left scratching their heads, wondering where to buy an effective treatment for head lice.

Meanwhile, the Vamousse brand has won the Independent Community Pharmacy magazine 'Pharmacy Product Of The Year - Best Advertising Campaign' award. The award is voted for by practising pharmacists. Their awareness and recommendation of the Vamousse Treatment and Protective range are key ingredients in the commercial success of these products, TyraTech said.

"I am very pleased with our achievements in the UK marketplace in the eight months since the launch of the Vamousse product range. We are confident of continued positive developments as our comprehensive UK distribution platform reaps the benefits of our highly engaging and effective marketing campaign."

Allenby Capital, joint broker to the company, said: "These additional listings support our revenue forecasts for 2015 and leave the company well placed to deliver maiden profits and (depending on the pace of expansion plans) positive cash flow in 2016."

Shares in TyraTech were up 1.3% at 5.7p in late afternoon trading.

]]>
Wed, 25 Feb 2015 15:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/66524/update-tyratech-says-two-more-uk-pharmacy-chains-to-stock-vamousse-77632.html
<![CDATA[News - TyraTech shampoo to make a splash across US Walmart stores ]]> https://www.proactiveinvestors.co.uk/companies/news/65806/tyratech-shampoo-to-make-a-splash-across-us-walmart-stores-76830.html Natural pesticide specialist TyraTech (LON:TYR) is to put another head lice treatment product on the shelves in Walmart stores across the US.

Walmart already stocks TyraTech’s Vamousse head lice treatment mousse, but from April the retail giant will also sell a preventive shampoo as well.

TyraTech, which focuses on nature-derived insect and parasite control products, has also signed a deal for its entire Vamousse range to be distributed by Cardinal Health, the third biggest distributor of pharmaceutical products in the US.

Bruno Jactel, chief executive, reckons the current head lice market in the USA is worth US$150mln in total and is driven by treatment products that are used on a reactive basis, when children are discovered to be hosting head lice and their eggs.

He believes there is potentially a much bigger untapped market of products that protect children and families at risk of infestation.

The deal with Cardinal Health, he added, presents the opportunity for Vamousse to reach more than 9,000 independent retail pharmacies in the US and follows a distribution deal for Vamousse signed with McKesson at the end of last year.

McKesson is the biggest distributor in the USA and serves more than 12,000 independently owned pharmacies.

Vamousse products are already available on amazon.com and drugstore.com in the USA and at Boots, Superdrug, Sainsbury's (LON:SBRY), Tesco (LON:TSCO), and Rowlands in the UK as well as other independent pharmacies.

]]>
Mon, 02 Feb 2015 16:16:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/65806/tyratech-shampoo-to-make-a-splash-across-us-walmart-stores-76830.html
<![CDATA[News - TyraTech unveils new CFO as Daniel Williams retires ]]> https://www.proactiveinvestors.co.uk/companies/news/65287/tyratech-unveils-new-cfo-as-daniel-williams-retires-76235.html Pest control specialist TyraTech (LON:TYR) has announced a new chief financial officer (CFO) to replace Daniel Williams, who is retiring.

Vince Morgus takes over as CFO and treasurer with immediate effect. He has held positions at professional services groups E&Y and Arthur Andersen, and joins TyraTech from Lulu Press, a private self-publishing ecommerce company, where he was CFO.

"He is a proven finance leader and corporate developer and his considerable experience will be invaluable to the company as we continue to expand into the retail markets of the USA and Europe,” said Bruno Jactel, chief executive of TyraTech.

Jactel also thanked Willians for his substantial contribution to the company since 2007.

]]>
Thu, 15 Jan 2015 08:18:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/65287/tyratech-unveils-new-cfo-as-daniel-williams-retires-76235.html
<![CDATA[News - TyraTech still set for strong growth, broker says ]]> https://www.proactiveinvestors.co.uk/companies/news/64523/tyratech-still-set-for-strong-growth-broker-says-75369.html Anticipating the timing of product introductions by retailers is tricky, hence the reduced full-year guidance announced by TyraTech (LON:TYR) this week.

The company's joint-broker, Allenby Capital, said the company has made exceptional progress over the last 12 months with Vamousse, the head lice treatment that has been launched in major retail chains in the US and the UK; however, as negotiations are wont to do, talks with retailers and distributors are taking longer than expected, prompting Allenby to amend its forecasts for 2015 and 2016.

The life sciences company focusing on nature-derived insect and parasite control products is now expected by Allenby to break even next year on revenues of US$8.3mln, and to push on in 2016 to make a normalised profit before tax of US$2.05mln on revenues of US$14.3mln.

"We still anticipate Walmart adding the Vamousse Protective Shampoo to its range in 2015," the broker said.

Disappointing though the profits downgrades are, the broker remains confident of management's growth through existing and new product introduction, and by expanding the distribution network.

Shares in TyraTech were up 1.1% at 4.55p on Friday.

]]>
Fri, 12 Dec 2014 15:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/64523/tyratech-still-set-for-strong-growth-broker-says-75369.html
<![CDATA[News - New products boost Tyratech sales ]]> https://www.proactiveinvestors.co.uk/companies/news/64123/new-products-boost-tyratech-sales-74929.html TyraTech’s (LON:TYR) Vamousse head lice treatment has made a strong start in Walmart stores following its introduction six months ago but launch delays elsewhere mean sales overall have lagged expectations.

The natural insecticides group now expects revenue for 2014 of US$4.8mln (US$1.4mln). Tyratech launched ten products in 2014 with fifty patents also pending and new product sales will amount to US$2.8mln against nothing in 2013.

Market expectations, however, were for sales this year of US$6mln. A decision by certain large US outlets to delay a review of Vamousse until the early part of 2015 is the main reason for the shortfall.

Losses will be slightly reduced at US$4.8mln (US$4.9mln) but these are greater than expected due to Vamousse launch costs allied to the lower than expected revenues.

Tyratech has also been affected by the acquisition of Novartis’ animal health business by Eli LIlly, which has slowed the commercial roll-out of the Natunex range.

Insect repellent Guardian has been sampling well on Amazon ahead of wider US distribution and a possible UK launch in 2015. 

Superdrug will also stock Vamousse this year in the UK in addition to Boots, Sainsbury's and Tesco.

Bruno Jactel, chief executive, said: “The company has a strong and growing pipeline of new products. 

“We firmly believe the company has strong growth potential and that the foundations are in place to realise significant future value."


]]>
Tue, 02 Dec 2014 07:51:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/64123/new-products-boost-tyratech-sales-74929.html
<![CDATA[News - TyraTech makes significant headway ]]> https://www.proactiveinvestors.co.uk/companies/news/62177/tyratech-makes-significant-headway-72691.html The launch of eight new TyraTech (LON:TYR) products this year has the company poised to enter a fast-growth phase.

Total revenues in the first half of 2014 from operations increased by 67% to US$1.3mln from US$0.8mln the year before, and that was with only three months' contribution from sales of its Vamousse Treatment mousse at Walmart, the world's biggest retailer, in the USA.

Gross profit increased by 233% to US$0.8mln from US$0.3mln, reflecting the launch of two Vamousse products and also six new Novartis Animal Health products under the Natunex brand.

New product launches may bring new revenue streams, but they also incur upfront costs, such as the US$1mln increase in US and UK marketing costs related to the Vamousse head lice treatment/shampoo and personal repellents.

Those costs contributed to a slightly deeper half year loss before tax of US$3.1mln compared to a loss of US$2.8mln the year before.

Cash at the end of June stood at US$0.6mln, down from US$3.7mln a year earlier, but since then has raised around US$5.7mln through a share issue.

"We have made significant headway with large distributors in the USA and in the UK and have backed our launch plans with strong and impactful marketing campaigns," said Bruno Jactel, TyraTech's chief executive officer.

"The customer feedback has been excellent so far and we feel confident that our products will bring safe and effective solutions to the current issues that customers are facing in fighting head lice, ticks and mosquitoes," he added.

Shares in TyraTech were up 0.9% at 7.95p in early trading, and are up 59% year-to-date.

]]>
Mon, 29 Sep 2014 08:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/62177/tyratech-makes-significant-headway-72691.html
<![CDATA[Media files - TyraTech CEO has ‘great expectations’ for Vamousse in UK ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/2643/tyratech-ceo-has-great-expectations-for-vamousse-in-uk-3023.html Thu, 28 Aug 2014 15:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/2643/tyratech-ceo-has-great-expectations-for-vamousse-in-uk-3023.html <![CDATA[News - TyraTech adds to blue-chip roster of retailers as Tesco & Sainsbury sign up for Vamousse ]]> https://www.proactiveinvestors.co.uk/companies/news/61184/tyratech-adds-to-blue-chip-roster-of-retailers-as-tesco-sainsbury-sign-up-for-vamousse-71633.html TyraTech (LON:TYR) has secured listings for its Vamousse head lice mousse and shampoo with two blue-chip British retailers.

Grocers Tesco and Sainsbury will join Boots and Superdrug in stocking the breakthrough new products when they hit the shelves in the UK next month.

The roll-out will be supported by a nationwide advertising campaign to coincide with the new school year.

TyraTech is building a head of steam for Vamousse, which is naturally derived, but is proven to be fast and effective in combatting and protecting against head lice.

Wal-Mart, the world’s largest retailer, stocks it in more than 4,000 stores in the US and it is available online at Amazon.com, drugstore.com and Walgreens.com.

TyraTech chief executive Bruno Jactel said: "We are very pleased to have secured, in a short period of time and ahead of the lice season, the inclusion of our Vamousse product range in a number of the major distributors in the pharmacy, health and beauty, and grocery distribution channels in the UK market.

“In addition, we are extending our distribution network in the USA on-line and through a network of independent pharmacies."

The shares were up 7.1% at 7.89p in lunchtime trading, and are up 58% year-to-date.

]]>
Wed, 27 Aug 2014 16:14:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/61184/tyratech-adds-to-blue-chip-roster-of-retailers-as-tesco-sainsbury-sign-up-for-vamousse-71633.html
<![CDATA[News - UPDATE - Tyratech launches Vamousse in UK through Boots and Superdrug ]]> https://www.proactiveinvestors.co.uk/companies/news/60031/update-tyratech-launches-vamousse-in-uk-through-boots-and-superdrug-70419.html --add share price--

TyraTech (LON:TYR) has raised £3.5mln to fund  the UK roll-out of its Vamousse head lice treatment range in Superdrug and Boots stores.

Bruno Jactel, Tyratech’s chief executive, said Vamousse’s UK launch was both ahead of the peak head lice season and schedule due to the success and interest generated in the US.

"To have obtained listings and partner relationships with both Boots and Superdrug further validates the potential of the Vamousse range of products," he said.

The brand is already on sale in the US through 4,000 Walmart stores and online through Amazon and Drugstore.

“The launch of the Vamousse product range in the UK is a further significant strategic step in the commercialisation of our strong intellectual property,” Jactel added.

The board believes that this could be the first step of a broader European expansion for Vamousse and other TyraTech products in the future ."

The natural insecticide specialist said the £3.5mln in new funds  was raised through an oversubscribed placing at 7p per share.

From the net proceeds, some £1.5 mln will provide marketing and inventory support for the Boots and Superdrug launch; £1.2mln will help with efforts to get Vamousse into other retailers and other countries while £0.6mln will provide additional working capital .

In May, Jactel told Proactive Investors that the preventative market was also an important market for the range.

“Head lice treatment products are usually an emergency buy, as people want to treat immediately, but the online distribution is always convenient and is a great way to go for the preventative shampoo.”

Shares shot up 13% today to 8.74p. 

]]>
Wed, 16 Jul 2014 15:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/60031/update-tyratech-launches-vamousse-in-uk-through-boots-and-superdrug-70419.html
<![CDATA[News - TyraTech confident about 2014 as extends product lines ]]> https://www.proactiveinvestors.co.uk/companies/news/59478/tyratech-confident-about-2014-as-extends-product-lines-69841.html Natural insecticide firm TyraTech (LON:TYR) had a busy 2013 and expects to launch ten new products by the end of this year, which will increase product revenues.

The firm has made massive strides recently, notably with the launch of Vamousse in over 4,000 Walmart stores in the US, where it said sales were increasing ahead of the main season - after schools return from summer holidays.

The product's treatment mousse and preventative shampoo are now available in the USA on Amazon.com, Drugstore.com and Walmart.com.

Another highlight is the distribution agreement with Novartis Animal Health leading to the launch of six new animal health products in USA under the Natunex brand.

Tyratech says it is now working hard to expand distribution channels in the USA and Europe.

In terms of the numbers, revenue for the 12 months decreased to US$1.4mln compared to US$3.6mln in 2012, mainly due to the absence of a collaborative revenue fee.

Operating expenses went down 17% to US$5.0 million (2012: US$6.0 million), while the net loss increased to US$4.9 million (2012: US$2.9 million).

Chief executive Bruno Jactel said that from the success and interest generated in the USA, it had become apparent other markets could be penetrated quicker than previously thought.

"In order to prepare for the UK launch of Vamousse, and to expand TyraTech's operations in Europe, the company is pleased to announce the appointment of Jonathan Hill as UK country manager, a senior executive with extensive operational experience in animal health and OTC [over the counter] products," he said.

He added: "The board anticipates that, as its products become more established and known amongst consumers, demand will become easier to predict. The medium term outlook for the company is extremely strong as our IP [intellectual property] continues to be commercialised into new products and geographies."

]]>
Thu, 26 Jun 2014 07:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/59478/tyratech-confident-about-2014-as-extends-product-lines-69841.html
<![CDATA[News - TyraTech passing the milestones ]]> https://www.proactiveinvestors.co.uk/companies/news/58359/tyratech-passing-the-milestones-68639.html TyraTech (LON:TYR) chief executive (CEO) Bruno Jactel told investors 2014 would be about delivery. Five-and-a-half months into the year, the company has made significant progress commercialising its range of nature-derived and safe insecticides.

Today’s announcement is just the latest in a series of significant milestones with the group revealing Amazon.com and Drugstore.com have agreed to take its head lice treatments and prevention products (click here for our earlier story).

Vamousse, its safe, natural, but 100% effective treatment for head lice, is already available on Amazon.com while Drugstore.com will start carrying the product line in the next few weeks.

It is the second important announcement from TyraTech in the last few weeks. On April 30 TyraTech revealed Novartis had launched Natunex, a new line of non-toxic biocides that provides highly effective and fast insect control in and around livestock production facilities.

The products will be distributed by Novartis Animal Health in the States, and taps both companies into a worldwide market predicted to be worth US$1bn by 2016.

Meanwhile, much excitement surrounds Vamousse, which as well as being available online has also been stocked in 4,100 Wal-Mart stores in the US since the beginning of April.

“Everything is going to plan,” CEO Jactel told Proactive Investors.

“We are now in all the Wal-Mart stores nationwide and our product seems to be selling well.

“Having said that, it is too early to draw any conclusions and it is the low part of the season.

“The logistic part seems to be working well. We are top of the class as far as quality of delivery is concerned.

“We have put in a very good system.”

The addition of Amazon and Drugstore adds two new routes to market, and, crucially, they are expected be a great launch pad for TyraTech’s head lice preventative shampoo.

“Head lice treatment products are usually an emergency buy, as people want to treat immediately, but the online distribution is always convenient and is a great way to go for the preventative shampoo. We now have two of the three biggest websites for over-the-counter-drugs in the USA.

“Our Vamousse treatment is available at Wal-Mart stores and online via Amazon.com and Drugstore.com, giving consumers several convenient ways to buy the product,”

The TyraTech boss also confirmed its commercial team will approach the big pharmacy chains when they review their product lines over the summer.

He also expects Vamousse to gain traction with the distributors that supply the 25,000 or so independent pharmacies that make up part of the pharmacy market.

“We are keeping the momentum going and widening our distribution network in the USA,” Jactel told Proactive.

“We are attracting new distributors all the time. It is a very exciting time.”

]]>
Mon, 19 May 2014 14:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/58359/tyratech-passing-the-milestones-68639.html